Sorry, had trouble getting the entire article but I think

New Post Public Reply Private Reply Replies (2) Message Board
DJknows DJknows #29499
753
Sorry, had trouble getting the entire article but I think it's all here (this is in today's San Francisco Chronicle):


Two drugs studied in Bay Area could lessen coronavirus deaths, hospitalizations
Photo of J.D. Morris
J.D. Morris April 23, 2020 Updated: April 23, 2020 6:25 a.m.

A man wearing a mask walks in Alamo Square Park across from the Painted Ladies, a row of historical Victorian homes in San Francisco. Two treatments being studied in the city could show promise against the coronavirus and COVID-19, the deadly disease it causes.

An image shows monoclonal antibodies at work in the body. These manufactured immune system proteins, which are designed to attack specific targets, are used to treat cancer and other disorders. One is being tested against the coronavirus.

Two drugs being studied by Bay Area doctors for use in fighting coronavirus infections may keep more COVID-19 patients alive and out of the hospital if proved effective.

One of the drugs, colchicine, is a cheap and common anti-inflammatory treatment for gout. UCSF is using it in a clinical trial of COVID-19 patients that is occurring entirely remotely. Patients receive colchicine or placebo pills in the mail and do not need to be seen in person.

The other drug, leronlimab, is a newer experimental treatment that was originally developed for use on HIV patients before being tested more recently on some people with breast cancer. Leronlimab is a monoclonal antibody made by the Vancouver, Wash., company CytoDyn, whose chief science officer is based in San Francisco.

One of the patients who has already been treated with the drug is Samantha Mottet, a 55-year-old resident of Seal Beach (Orange County). She fell ill, primarily with exhaustion, shortly after her husband returned from a trip to the East Coast last month. She was eventually admitted to the hospital at UCLA, where she received an organ transplant 14 years ago, after testing positive for the coronavirus.

Her condition worsened in the hospital and she was placed on a ventilator. The first round of drugs Mottet was given did not improve her COVID-19 symptoms. Then, with her husband’s approval, her doctor administered leronlimab.

Mottet told The Chronicle that the drug was her “last hope” — and it worked. Within 24 hours, she needed less oxygen, and she was taken off the ventilator a few days later. She said she has experienced no side effects.

“All I know is I’m just thankful to be here today,” Mottet said. “This drug worked for me and I hope it works for other people.”

Dr. Warner Greene, a senior investigator with the Gladstone Institutes who has been studying the coronavirus, said leronlimab appears to be “more surgical in its effect.” Colchicine, though well known and widely used, “seems like a blunt instrument for the job at hand,” he said.

Greene said leronlimab is a more targeted kind of drug that would be “interfering with a fundamental part of the process that is causing the trouble.”

“Colchicine may be doing that, but it’s having its effect all over the body,” he said. “That said, if it blocked the cytokine storm ... that would be wonderful.”

Doctors studying leronlimab think it could be broadly effective. While CytoDyn would like to use the drug on ICU patients, its greatest benefit will likely be on patients in earlier stages of COVID-19 — hospitalized people with symptoms more severe than mild shortness of breath, said Lalezari of CytoDyn.

Dr. Bruce Patterson, CEO of the San Carlos single-cell diagnostic company IncellDx that has been working on leronlimab, said the drug is exciting because it appears to impact some of the most essential elements of the viral disease, “not just a piece of what COVID is all about.”

“This is the ideal drug to meet everybody’s needs about reopening the country,” Patterson said. “If we had something that we could say we can treat the severe (patients) and we can keep the mild-to-moderates from getting severe, then it becomes the flu. Then we’re not so scared of people getting infected.”

J.D. Morris is a San Francisco Chronicle staff writer. Email: jd.morris@sfchronicle.com Twitter: @thejdmorris


https://www.sfchronicle.com/health/article/Tw...219896.php









CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fall Pest Risks Linger as Mild Weather Extends Threat

Updated Category News Views 104

A cold snap is not a magic off switch for mosquitoes, ticks, or rodents, and that is the sober point behind the National Pest Management Association's fall and winter 2026 Public Health Pest Index. The group is flagging conditions, not predicting that every household in a named city will face an infestation or illness. Still, mild temperatures, rain, flooding, and plenty...

Continue Reading
Commodity Rout Tests a Market Already Short on Nerve

Updated Category News Views 56

Some weeks the tape merely wobbles; this one started throwing furniture. By midday Wednesday, traders were staring at sharp declines in gold, silver, crude and copper while the major equity benchmarks remained underwater for the week. That is an unpleasant combination. When growth-sensitive commodities and the usual hard-asset hiding places are all getting sold,...

Continue Reading
CVRx Lawsuit Deadline Follows a Brutal 59.76% Plunge

Updated Category News Views 160

A 59.76% one-day wipeout has a way of stripping the varnish off every upbeat corporate story. For CVRx investors, the hard fact is that the shares fell $3.55 to close at $2.39 on August 7, 2026, after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That kind of disclosure does not merely dent confidence; it forces...

Continue Reading
Hyster-Yale’s $135 Million Convert Carries Real Cost

Updated Category News Views 63

Forklift makers do not usually get to hide a 7.50% borrowing cost behind glossy financing jargon. Hyster-Yale has priced $135 million of convertible senior notes due in 2031, lifting the deal from the originally announced $125 million. There is also an option for initial purchasers to take another $20 million. For NYSE:HY shareholders, this is not a simple debt cleanup....

Continue Reading
Norfolk Southern's 200-Year Campaign Meets a Hard Market

Updated Category News Views 111

Two centuries of railroad history can stir the blood, but it does not move a single carload by itself. Norfolk Southern has opened its 200-year railroading celebration with the GeneratioNS campaign, a three-locomotive NS 200 commemorative series, and plans for public events across its network. For a railroad with deep roots and very modern operational pressures, this is...

Continue Reading
Why Lear’s PACE Award Matters Beyond Seat Warmers Today

Updated Category News Views 102

Seat foam and wiring seldom make investors sit upright, yet Lear has managed to turn that unglamorous corner of the vehicle into something worth watching. The company’s Modular Thermal Comfort Systems just won a 2026 Automotive News PACE Award, a respected supplier-industry nod for innovation and business performance. Awards alone do not pay anybody’s bills, and I...

Continue Reading
Common Tiger Bets $499 on Better Outdoor Seating Design

Updated Category News Views 59

A chair that refuses to slump into the camping aisle is Common Tiger's whole argument, and frankly it is a smarter argument than another flimsy fold-up contraption pretending comfort is optional. The Los Angeles, female-founded and women-owned brand is launching with one product, The Daymaker, after four years of development. That is a long runway for a debut chair, which...

Continue Reading
Breakthrough T1D Gala Puts Research Progress First

Updated Category News Views 49

One person living without insulin after a cell-therapy trial is the detail that cuts through all the ballroom polish tonight. Breakthrough T1D's 53rd Annual New York City Promise Gala lands at the Plaza Hotel during National Diabetes Awareness Month, and it carries a message worth handling carefully: research can produce extraordinary outcomes, but one participant's...

Continue Reading
Frosty Animatronics Put Nostalgia on Lowe's Shelves

Updated Category News Views 142

A moving corncob pipe is not anybody's idea of a macroeconomic signal, yet holiday aisles are built on precisely these little jolts of recognition. Gemmy has teamed with Warner Bros. Discovery Global Consumer Products to place a new animated Frosty the Snowman collection exclusively at Lowe's for the 2026 holiday season. It is cheerful retail business, not earthshaking...

Continue Reading
CHN Energy's Indonesia Record Deserves a Hard Look

Updated Category News Views 50

Twenty years of boots sinking into swamp mud tells a sturdier story than a polished anniversary slogan. CHN Energy says it entered Indonesia's energy market two decades ago and has since built an operating presence around reliable electricity, local training and community work. In a country scattered across thousands of islands, dependable power is not some decorative...

Continue Reading

Top 5 Most Recently Viewed Articles

Arasan Chip Systems Unveils Advanced eUSB2 Solutions for IoT

Updated Category News Views 300

Arasan's Innovative USB2 Solutions Now Available Arasan Chip Systems, a recognized leader in semiconductor intellectual property for mobile and automotive systems on chips (SoCs), has announced the launch of its new Embedded USB2 (eUSB2) IP Core. This cutting-edge technology aims to empower a wide range of electronic devices with efficient connectivity options. Targeting...

Continue Reading
Class Action Filed Against MongoDB: Key Insights and Impacts

Updated Category News Views 98

Overview of the Class Action Lawsuit Against MongoDB Pomerantz LLP has recently brought attention to a significant legal issue concerning MongoDB, Inc. (NASDAQ: MDB). The law firm has filed a class action lawsuit that raises serious questions about the company's compliance with securities laws and the potential consequences for investors. Allegations Explained This...

Continue Reading
Rycor LLC's Strategic Push in Commercial Heating Solutions

Updated Category News Views 136

Expanding Horizons: Rycor LLC Enters Commercial Market RYCOR LLC, well-known as the Northeast's authority in energy-efficient residential mini-splits, is broadening its horizons to embrace the commercial heating and cooling sector. This strategic move represents a significant enhancement in their service offerings, targeting multi-family housing developments, office...

Continue Reading
Successful Charity Ride Brings Community Together for a Cause

Updated Category News Views 148

Second Annual Solstice Century Ride Makes a Big Impact During the longest day of the year, fifty-two enthusiastic riders took on a 100-mile challenge as they participated in the second annual Solstice Century Ride. The event, held at the picturesque Whalon Lake Forest Preserve, proved to be more than just a cycling challenge; it became a powerful avenue for community...

Continue Reading
QuickBooks' Intelligent AI Tool Revolutionizes Business Insights

Updated Category News Views 126

Revolutionizing Business Insights with Intelligent AI In today's fast-paced business environment, understanding how to leverage technology for better decision-making is crucial. Enter QuickBooks' Intelligent AI Dashboard Agent, a powerful tool that has been recognized by industry experts as the best all-in-one solution for real-time business insights in 2025. This...

Continue Reading